| scholarly article | Q13442814 |
| P2093 | author name string | P J Lee | |
| S Singh | |||
| P J Shim | |||
| R B Raffa | |||
| Y-Y Chang | |||
| M E Joseph | |||
| R Judge | |||
| C Ruchalski | |||
| I C Madhani | |||
| J S John | |||
| K Kudratov | |||
| L M Huynh | |||
| R C Guduru | |||
| R Kimmey | |||
| S Cangoz | |||
| S J Chempakaseril | |||
| S T John | |||
| P2860 | cites work | A clinical trial to maintain glycemic control in youth with type 2 diabetes | Q36340078 |
| Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q36549321 | ||
| Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. | Q36891945 | ||
| Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes | Q37139427 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes | Q37244353 | ||
| Glucose control by the kidney: an emerging target in diabetes | Q37424426 | ||
| Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications | Q37439364 | ||
| Dapagliflozin: where does it fit in the treatment of type 2 diabetes? | Q37593086 | ||
| Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent | Q37697842 | ||
| Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus | Q37703184 | ||
| Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. | Q37764285 | ||
| Dapagliflozin: more than just another oral glucose-lowering agent? | Q37812136 | ||
| Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'. | Q37815524 | ||
| SGLT inhibitors as new therapeutic tools in the treatment of diabetes | Q37864206 | ||
| Diabetes mellitus: new drugs for a new epidemic | Q37879307 | ||
| SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. | Q37981884 | ||
| TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity | Q38387199 | ||
| Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma | Q38406543 | ||
| Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study | Q38435071 | ||
| Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck | Q40609497 | ||
| Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes | Q42021894 | ||
| Antigenicity of insulin: diabetes induced by specific antibodies | Q42267512 | ||
| Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. | Q42944430 | ||
| Dapagliflozin, an SGLT2 inhibitor, for diabetes | Q42977474 | ||
| The stunned beta cell: a brief history | Q43073326 | ||
| (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment | Q43123822 | ||
| Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study | Q43143768 | ||
| Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus | Q43199877 | ||
| Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3β, Snail1, and β-catenin in renal proximal tubule cells | Q43218265 | ||
| In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans | Q43227334 | ||
| SGLT gene expression in primary lung cancers and their metastatic lesions | Q43709713 | ||
| Normalization of cytoplasmic calcium response in pancreatic beta-cells of spontaneously diabetic GK rat by the treatment with T-1095, a specific inhibitor of renal Na+-glucose co-transporters. | Q43978130 | ||
| Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. | Q43993113 | ||
| Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus | Q44007780 | ||
| Regulatory mechanisms of intracellular distribution of Na+-dependent glucose transporter and the role in recovery from cellular injury | Q45172046 | ||
| Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus | Q46171591 | ||
| Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats | Q46406143 | ||
| Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models | Q46516165 | ||
| Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes | Q46764321 | ||
| SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: a novel cellular rescue mechanism? | Q46783993 | ||
| Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
| Survival of cancer cells is maintained by EGFR independent of its kinase activity | Q24309274 | ||
| Standards of medical care in diabetes--2012 | Q24632533 | ||
| Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 | ||
| The sodium/glucose cotransport family SLC5 | Q28204259 | ||
| The SLC2 family of facilitated hexose and polyol transporters | Q28204545 | ||
| Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies | Q28237011 | ||
| Expression cloning and cDNA sequencing of the Na+/glucose co-transporter | Q28306556 | ||
| Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095 | Q28346436 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients | Q33451134 | ||
| Molecular mechanism of insulin resistance in obesity and type 2 diabetes | Q33893897 | ||
| Genotyping analysis of Helicobacter pylori using multiple-locus variable-number tandem-repeats analysis in five regions of China and Japan. | Q34010205 | ||
| Phloridzin: biosynthesis, distribution and physiological relevance in plants | Q34107672 | ||
| SGLT2 inhibition--a novel strategy for diabetes treatment | Q34117872 | ||
| The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose | Q34121476 | ||
| Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives | Q34150475 | ||
| Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial | Q34153496 | ||
| Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors | Q34222752 | ||
| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes | Q34227891 | ||
| Oral antihyperglycemic therapy for type 2 diabetes: scientific review | Q34492673 | ||
| Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level | Q34575066 | ||
| Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise | Q34646948 | ||
| Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. | Q34657372 | ||
| Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus | Q34876148 | ||
| Community-based lifestyle interventions to prevent type 2 diabetes | Q35207016 | ||
| Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass | Q35756418 | ||
| Minireview: Epigenetics of obesity and diabetes in humans | Q35762714 | ||
| Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs | Q35950011 | ||
| Phlorizin: a review | Q35995949 | ||
| A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes | Q47916425 | ||
| United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. | Q50109154 | ||
| Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. | Q51366978 | ||
| Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. | Q51369293 | ||
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. | Q51372081 | ||
| Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. | Q51396403 | ||
| Autoantibodies in type 1 diabetes. | Q51456535 | ||
| Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. | Q51759708 | ||
| Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. | Q51763308 | ||
| Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats. | Q54024831 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 350-359 | |
| P577 | publication date | 2013-06-12 | |
| P1433 | published in | Journal of Clinical Pharmacy and Therapeutics | Q15753553 |
| P1476 | title | The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors | |
| P478 | volume | 38 |
| Q34181385 | A Review on the Relationship between SGLT2 Inhibitors and Cancer. |
| Q38537119 | A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans |
| Q89627944 | Dysplastic urothelial changes accompany empagliflozin administration in urinary bladder of experimental diabetes |
| Q49617047 | Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization |
| Q88871989 | Insulin dependent and independent normalization of blood glucose levels reduces the enhanced rewarding effects of nicotine in a rodent model of diabetes |
| Q34412028 | Ipragliflozin: first global approval |
| Q40236660 | Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed? |
| Q53482444 | Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. |
| Q38654762 | SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials |
| Q47642298 | SGLT2 inhibitors: are they safe? |
| Q35359647 | Xenobiotic transporter expression along the male genital tract |
Search more.